Compare PPL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPL | RPRX |
|---|---|---|
| Founded | 1920 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4B | 28.4B |
| IPO Year | 2007 | 2020 |
| Metric | PPL | RPRX |
|---|---|---|
| Price | $35.50 | $68.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 9 |
| Target Price | $40.22 | ★ $72.00 |
| AVG Volume (30 Days) | ★ 7.9M | 3.1M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.18% | 1.37% |
| EPS Growth | ★ 32.50 | N/A |
| EPS | ★ 1.59 | 1.03 |
| Revenue | ★ $9,042,000,000.00 | $2,378,193,000.00 |
| Revenue This Year | $6.89 | $49.27 |
| Revenue Next Year | $6.26 | $9.11 |
| P/E Ratio | ★ $22.52 | $66.52 |
| Revenue Growth | ★ 6.85 | 5.06 |
| 52 Week Low | $31.56 | $37.31 |
| 52 Week High | $40.11 | $70.37 |
| Indicator | PPL | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.18 | 65.56 |
| Support Level | $34.79 | $55.48 |
| Resistance Level | $35.58 | N/A |
| Average True Range (ATR) | 0.55 | 1.58 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 36.56 | 65.28 |
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.